| |
Hall A
|
Hall B
|
Hall C |
|
08:30-19:00
|
Registration |
|
|
|
10:00-12:00 |
Satellite Symposium sponsored by Sanofi Aventis :
The role of the renin–angiotensin system in the prevention of new diabetes |
Satellite Symposium sponsored by Novartis:
Early intervention for type 2 Diabetes Mellitus: Is it important? Is it possible? Is it practical? |
|
|
13:30-15:30 |
Satellite Symposium sponsored by Bristol-Myers Squibb and Merck Sharp & Dohme: Epidemiology of pre-diabetes and metabolic syndrome. Potential therapeutic role of dual alpha/gamma PPAR activators |
Satellite Symposium sponsored by Bayer: Acarbose – a therapeutic bridge between pre-and established type 2 diabetes
|
|
|
16:00-18:00 |
|
Satellite Symposium sponsored by Merck Sharp and Dohme
The Promises and Challenges of Managing Metabolic Syndrome/Diabetes in the Clinic
|
Satellite Symposium sponsored by Merck KGaA
Prediabetes: The Challenge to Society
|
|
18:30 |
Opening Ceremony
Followed by
Get-Together Reception
|
|
|
| |
Hall A
|
Hall B
|
Hall C
|
Hall D |
|
08:30-10:30
|
Plenary Session: Setting the Scene. Glucose Intolerance – What's in a
Name?
|
|
|
|
|
10:30-11:00 |
Coffee Break |
|
|
|
|
11:00-12:30 |
Plenary Session: Are we Ready to Treat the Metabolic Syndrome?
|
|
|
|
|
12:30-14:00 |
Lunch Break, Exhibition and Poster Viewing |
|
|
|
|
14:00-15:30 |
"Polylogue" – The Metabolic Syndrome |
"Prediabetes" and the Metabolic Syndrome: Characteristics
and Risks
|
Mechanisms of Dysglycemia |
Metabolic Syndrome - Epidemiology |
|
15:30-16:00 |
Coffee Break, Exhibition and Poster Viewing |
|
16:00-17:30 |
Obesity and its Metabolic Consequences
|
"Prediabetes" and the Metabolic Syndrome in the
Young |
Epidemiology of "Prediabetes" and the Metabolic
Syndrome |
Metabolic Syndrome – Genetics and Clinical Features |
|
18:00-20:00 |
Satellite Symposium sponsored by Takeda
Thizolidinediones: Can they Preserve Beta Cell Function and Prevent
Cardiovascular Disease? |
Satellite Symposium sponsored by Sanofi-Aventis
CB1 Blockade: New Approach for the Management of
Cardiovascular Risk in Patients with Metabolic Syndrome? |
|
|
| |
Hall A
|
Hall B
|
Hall C
|
|
08:30-10:30
|
Plenary Session: Pharmacological Prevention of Diabetes in High-Risk
Populations
Supported by an unrestricted educational grant from AstraZeneca |
|
|
|
10:30-11:00 |
Coffee Break, Exhibition and Poster Viewing |
|
|
|
11:00-12:30 |
Non-Pharmacological Prevention of Diabetes in High-Risk Population
|
Intervening in "normal" populations: Screening
and Health Economics |
Dysglycemia – Predictions and Detection |
|
12:30-14:00 |
Lunch Break, Exhibition and Poster Viewing |
|
14:00-15:30 |
New drugs for "Prediabetes", Metabolic Syndrome and their CVD
consequences
Supported by an unrestricted educational grant from Novo Nordisk |
Pharmacological Intervention in CVD Risk Factors – Components of
the Metabolic Syndrome
Supported by an unrestricted educational grant from Sanofi-Aventis |
Nutrition and Exercise Effects on Glucose Metabolism |
|
15:30-16:00 |
Coffee Break, Exhibition and Poster Viewing |
|
16:00-17:30 |
Epidemiology of CVD in "Prediabetes" and the
Metabolic Syndrome |
Mechanisms leading to CVD in "Prediabetes" and
the Metabolic Syndrome |
Pharmacological and other Therapeutic Modalities |
|
17:45-19:45 |
Satellite Symposium sponsored by Laboratoire Fournier SA
Clinical Approach and Management of Diabetes and Metabolic Syndrome
|
|
Satellite Symposium sponsored by Merck KGaA
Dyslipidemia and the Metabolic Syndrome: Critical Issues in Improving CVD Risk Reduction
|
|
20:30
|
Farewell Dinner (optional)
Dinner Debate: Prediabetes or IGT |
|
|
| |
Hall A
|
Hall B
|
Hall C |
|
08:30-10:30
|
Plenary Session: Prevention of CVD in "Prediabetes"
– Primary and Secondary
Supported by an unrestricted educational grant from
Sanofi-Aventis |
|
|
|
10:30-11:00 |
Coffee Break, Exhibition and Poster Viewing |
|
11:00-12:15
|
Dysglycemia and Coronary Artery Disease |
The Coronary Patient with Dysglycemia
|
Metabolic Abnormalities in Coronary Artery Disease |
|
12:15-13:30
|
Lunch Break, Exhibition and Poster Viewing |
|
13:30-15:30
|
Plenary Session: Future Directions and Conclusions
|
|
|
